EUVIMEDEUVIMED entdecken
Übersichtsarbeit

STING agonists in tumor therapy: structural pharmacology, determinants of productive activation, and barrier-matched therapeutic strategies

Chenyi Li, Lanxiang Wu

Biochemical Pharmacology · 2026-10 · 252 · 118233

DOI: 10.1016/j.bcp.2026.118233 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-10. Verfasst von Chenyi Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing 400…. Hauptthemen laut MEDLINE: Membrane Proteins, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 111 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cyclic GMP-AMP synthase-stimulator of interferon genes pathway is a central innate immune axis that connects cytosolic DNA sensing with type I interferon production, dendritic-cell activation, and downstream T-cell priming. These functions have positioned stimulator of interferon genes (STING) as an attractive therapeutic target in cancer, driving the development of cyclic dinucleotides, non-nucleotide small molecules, and formulation-enabled agonist platforms. Yet early clinical experience has revealed a recurring gap between measurable target engagement and durable antitumor benefit. Understanding this gap requires a pharmacological analysis that moves beyond pathway-level description and considers agonist chemistry, binding mode, intracellular trafficking, and exposure pattern together with the tumor-context determinants that control productive immune conversion. In this review, we summarize the structural, molecular, and biochemical basis of STING agonism, with emphasis on ligand recognition, species-selective determinants, trafficking requirements, and the pharmacological consequences of route of administration and formulation design. We then use a barrier-oriented perspective to examine four recurrent limitations on productive STING agonism in tumors: compartment mismatch, metabolic constraints, extracellular cyclic GMP-AMP (cGAMP) neutralization, and chronic output drift. These barriers help explain why pathway engagement may not consistently produce antigen-presenting cell (APC)-centered interferon output, T-cell priming, and durable antitumor immunity. We close by mapping therapeutic strategies to the barrier each strategy is most likely to overcome and by outlining biomarker-guided principles for designing STING activation that is therapeutically productive, rather than merely detectable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsNeoplasmsAntineoplastic AgentsHumansSTING ProteinAnimalscGAS-STING Signaling Pathway

Stichwörter der Autor:innen

Cancer immunotherapyENPP1Metabolic constraintsPharmacological barriersTumor microenvironmentcGAMPcGAS–STING

Substanzen

Membrane ProteinsSTING ProteinSTING1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing 400016, China. Electronic address: lichenyi_0817@163.com.
  • Pharmacogenetics and Pharmacogenomics Laboratory, School of Pharmacy, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing 400016, China. Electronic address: lxwu@cqmu.edu.cn.

Förderung

  • Natural Science Foundation of Chongqing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Li, C., & Wu, L. (2026). STING agonists in tumor therapy: structural pharmacology, determinants of productive activation, and barrier-matched therapeutic strategies. Biochemical Pharmacology, 252, 118233. https://doi.org/10.1016/j.bcp.2026.118233

Vancouver

Li C, Wu L. STING agonists in tumor therapy: structural pharmacology, determinants of productive activation, and barrier-matched therapeutic strategies. Biochemical Pharmacology. 2026;252:118233. doi:10.1016/j.bcp.2026.118233

BibTeX
@article{Li2026,
  author = {Li, Chenyi and Wu, Lanxiang},
  title = {STING agonists in tumor therapy: structural pharmacology, determinants of productive activation, and barrier-matched therapeutic strategies},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {252},
  pages = {118233},
  doi = {10.1016/j.bcp.2026.118233}
}
Kostenlos starten →